Combination antiretroviral therapy

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Funders: Indian Council of Medical Research and 1 more

Humans1
Animals1

Outcomes

Neurodegeneration

downin rhesus monkeys1

1 study

Combination antiretroviral therapy protects against neurodegeneration in rhesus monkeys.
“Combination antiretroviral therapy prevents SIV-induced aging in the hippocampus and neurodegeneration throughout the brain”
Animalsin SIV-infected rhesus macaquesbrain
Combination antiretroviral therapy prevents SIV-induced aging in the hippocampus and neurodegeneration throughout the brain
Journal of neurovirology30 Oct 2025

GFAP

downin rhesus monkeys1

1 study

Combination antiretroviral therapy decreases GFAP in rhesus monkeys.
“cART reduced SIV-induced accelerated aging (p16 and SIRT1) in the hippocampus and neurodegeneration and GFAP expression in the frontal lobe.”
Animalsin SIV-infected rhesus macaquesfrontal lobe
Combination antiretroviral therapy prevents SIV-induced aging in the hippocampus and neurodegeneration throughout the brain
Journal of neurovirology30 Oct 2025

Associations

Immunosenescent T-cell proportion

downin humans1

1 study

Combination antiretroviral therapy is associated with immunosenescent T-cell proportion in humans (23% (6-80) versus 28% (4-52)).
“The proportion of immunosenescent T cells (CD8+CD28−CD57+KLRG1+) was lower in the ART+ group [23% (6-80)] than in the ART- group [28% (4-52)].”
HumansHIV-1 infection; treated versus treatment-naïve individualsT cellprolonged
Immunosenescence and immune dysfunction in treated and untreated HIV-infected individuals
The Indian journal of medical research1 Aug 2026

More on Immunosenescent T-cell proportion